ESR1 and breast cancer: CCAR2 depletion reduces the tumorigenic potential of ERα-negative breast cancer cells5, and increased expression of CCAR2 has been associated with worsened relapse-free survival of ERα-positive and ERα-negative breast cancer patients4,5.